



دانشکده پزشکی گروه انجمن و قارچ‌شناسی

عنوان پایان نامه

بررسی تاثیر آنتی سرم های پلی اسپینیک ضد آنتی ژن های کیست هیدراتیک بر رشد تو موز ملا نو مادر موش سوری

شماره طرح تحقیقاتی: ۳۹۳۱۰۷

نویسنده: فرشته خفائی نوده

تحت راهنمایی: جناب آقای دکتر یوسفی

تحت مشاوره: دکتر سید حسین جازمی - دکتر سپیده طلوعی

مرداد ۹۴

## بررشد تومور ملانوما در موش سوری

### مقدمه

کیست هیداتیک مرحله لاروی اکینوкокوس گرانولوزوس است که عامل ایجاد بیماری هیداتیدوز در انسان و حیوانات اهلی است. تاثیر آنتی ژنهای مختلف این انگل در پیشگیری از رشد سلولهای توموری در مطالعات مختلف اثبات شده است. لذا در این مطالعه تاثیر تزریق آنتی سرم های ضد آنتی ژن های کیست هیداتیک بر رشد سرطان ملانوما در مدل حیوانی بررسی گردیده است.

### روشها

در این مطالعه تجربی آنتی سرمهای ضد آنتی ژنهای مختلف کیست هیداتیک در خرگوش تهیه و به موشهای C57/BLAC که سلولهای ملانوما دریافت کرده بودند تزریق شد. مساحت تومورها درگروههای دریافت کننده آنتی سرم و گروه دریافت کننده سرم نرمال خرگوش به عنوان گروه شاهد مقایسه شد، سپس نتایج با استفاده از نرم افزار آمار SPSS و آزمون ONE WAY ANOVA مورد تجزیه و تحلیل قرار گرفت.

### یافته ها

میانگین مساحت تومور موش هایی که آنتی سرم ضد مایع کیست، آنتی ژن خام پروتواسکولکس، آنتی ژن دفعی ترشخی پروتواسکولکس و آنتی ژن لایه کوتیکولی دریافت کرده بودند تفاوت معنی داری با میانگین مساحت تومور در گروه های شاهد نداشت.

### نتیجه گیری

نتایج این مطالعه نشان داد که تزریق آنتی سرم ضد آنتی ژنهای مختلف کیست هیداتیک به موش های دریافت کننده سلولهای ملانوما تاثیری در کاهش رشد تومور نداشته است و لذا پیشنهاد می گردد تاثیر انتقال سلولهای ایمنی بر رشد تومور بررسی گردد.

## فهرست مطالب

فصل اول

- مقدمه ..... ۲
- تاریخچه انگل ..... ۲
- گونه های مختلف جنس اکینوкокوس ..... ۲
- مرفولوژی ..... ۳
- تخم ..... ۳
- لارو یا متاستود ..... ۴
- کرم بالغ ..... ۵
- چرخه زندگی انگل ..... ۶
- سرطان ..... ۷
- سرطان پوست ..... ۷
- تاریخچه ایمونوتراپی ..... ۷
- پاسخ ایمنی در برابر تومورها ..... ۸
- ارتباط انگل و سرطان ..... ۸
- ضرورت انجام کار ..... ۹
- اهداف کلی و اختصاصی ..... ۱۰
- هدف کلی ..... ۱۰
- اهداف جزئی ..... ۱۰
- فرضیات ..... ۱۱

فصل دوم

- تهیه آنتی ژنهای مختلف کیست هیداتیک ..... ۱۳
- آنتی ژن مایع کیست ..... ۱۳
- آنتی ژن خام پروتواسکولکس ..... ۱۳
- آنتی ژن دفعی - ترشحي پروتواسکولکس ..... ۱۴
- آنتی ژن لایه کوتیکولی و ژرمینال ..... ۱۴
- اندازه گیری میزان پروتئین آنتی ژن ها ..... ۱۴
- تهیه آنتی سرم ضد آنتی ژنهای کیست هیداتیک ..... ۱۵
- مخلوط کردن آنتی ژن ها با ادجوانت ..... ۱۵

.....	تزریق آنتی ژنها به خرگوش.....	۱۵
از	خونگیری	
.....	خرگوشها.....	۱۵
.....		
۱۶	آزمایش الایزا.....	
۱۷	طرز تهیه محلولها.....	
الایزا	آماده سازی پلیت و انجام تست الایزا	۱۸
.....		
۱۹	کشت سلولی .....	
زیر	سلولهای	ملانوما
.....	میکروسکوپ.....	۲۰
۲۱	آزمایش اول.....	
به	تزریق سلولهای	ملانوما
.....	موشها.....	۲۱
.....	تزریق آنتی سرم به موشها.....	
.....		۲۲
۲۳	آزمایش دوم.....	
به	تزریق سلولهای	ملانوما
.....	موشها.....	۲۳
.....	تزریق آنتی سرم به موشها.....	
.....		۲۳
محاسبه	اندازه گیری قطر تومور و محاسبه مساحت.....	۲۴
	<b>فصل سوم</b>	
۲۶	نتایج.....	
.....	محاسبه مساحت تومور در موشهای مربوط به آزمایش	
.....	اول.....	۲۶
.....	جدول مربوط به اولین اندازه گیری گروه	
.....	اول.....	۲۶
.....	جدول مربوط به دومین اندازه گیری گروه اول	
.....	.....	۲۷
.....	جدول مربوط به سومین اندازه گیری گروه	
.....	اول.....	۲۸
.....	جدول مربوط به چهارمین اندازه گیری گروه	
.....	اول.....	۲۸
.....	محاسبه مساحت تومور در موشهای مربوط به آزمایش	
.....	دوم.....	۲۹
.....	جدول مربوط به اولین اندازه گیری گروه	
.....	دوم.....	۲۹
.....	جدول مربوط به دومین اندازه گیری گروه	
.....	دوم.....	۳۰

- جدول میانگین اندازه گیری قطر تومور در گروههای اول و

۳۱

دوم.....

- **فصل چهارم**

- بحث و نتیجه

گیری.....

.....

۳۳

.....

- پیشنهادات

.....

.....

۳۵

.....

- منابع

.....

.....

۳۶

.....

1. Jahangir, A., et al., *Echinococcosis/hydatidosis in Ilam province, western Iran*. Iranian journal of parasitology, 2013. **8**(3): p. 417 .
2. Teichmann, A., *Clonagem e expressão da proteína 14-3-3ε1 de Echinococcus granulosus em Escherichiacoli*. 2010 .
3. Moro, P. and P.M. Schantz, *Echinococcosis: a review*. International Journal of Infectious Diseases, 2009. **13**(2): p. 125-133 .
4. Zhang, W., J. Li, and D.P. McManus, *Concepts in immunology and diagnosis of hydatid disease*. Clinical microbiology reviews, 2003 : ( \ ) \ ٦ . p. 18-36 .
5. Thevenet, P.S., et al., *Viability and infectiousness of eggs of Echinococcus granulosus aged under natural conditions of inferior arid climate*. Veterinary parasitology, 2005. **133**(1): p. 71-77 .
6. Khoo, K.-H., et al., *Structural characterization of the N-glycans from Echinococcus granulosus hydatid cyst membrane and protoscoleces*. Molecular and biochemical parasitology, 1997 : (٢)٨٦ .p. 237-248.
7. Engin, G., et al., *Hydatid disease with unusual localization*. European radiology, 2000. **10**(12): p. 1904-1912 .
8. Dahniya, M., et al., *The imaging appearances of hydatid disease at some unusual sites*. The British journal of radiology, 2001. **74**(879): p. 283-289 .
9. Pedrosa, I., et al., *Hydatid Disease: Radiologic and Pathologic Features and Complications 1: (CME available in print version and on RSNA Link)*. Radiographics, 2000. **20**(3): p. 795-817 .
10. Ciftçioğlu, M., et al., *Fine needle aspiration biopsy in hepatic Echinococcus multilocularis*. Acta cytologica, 1997. **41**(3): p. 649-652 .
11. Özek, M.M., *Complications of central nervous system hydatid disease*. Pediatric neurosurgery, 1994. **20**(1): p. 84-91 .
12. Sahni, J., et al., *Submandibular hydatid cyst caused by Echinococcus oligarthrus*. Journal of Laryngology & Otology, 2000. **114**(06): p. 473-476 .
13. Chemale, G., et al., *Echinococcus granulosus antigen B hydrophobic ligand binding properties*. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2005. **1747**(2): p. 189-194 .
14. DEMATTEIS, S., et al., *Antibody and Th1/Th2-type responses in BALB/c mice inoculated with live or dead Echinococcus granulosus protoscoleces*. Parasite immunology, 1999. **21**(1): p. 19-26 .
15. Thompson, R.A . and D.P. McManus, *Towards a taxonomic revision of the genus Echinococcus*. TRENDS in Parasitology, 2002. **18**(10): p. 452-457 .
16. McManus, D. and N. Barrett, *Isolation, fractionation and partial characterization of the tegumental surface from protoscoleces of the hydatid organism, Echinococcus granulosus*. Parasitology, 1985. **90**(01): p. 111-129 .
17. Walker, M., et al., *In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes*. Journal of Antimicrobial Chemotherapy, 2004. **54** : ( ٣ ) p. 609-616 .
18. Rafati, M., M. Ghotbi, and H. Ahmad Nia, *Principle of disease prevention and surveillance*. Surveillance Systems of Non-Communicable Diseases, 2008 .
19. Mathers, C., D.M. Fat, and J.T. Boerma, *The global burden of disease: 2004 update* : ٢٠٠٨ . World Health Organization .

20. Hajian, K., A. Firouzjahi, and M. Kia, *pattern of age distribution of different cancers Babol*, 2001. Pejouhesh, 2003. **27**(3): p. 239-245 .
21. Afzali, M., et al., *Epidemiology of skin cancer and changes in its trends in Iran*. KAUMS Journal (FEYZ), 2013. **17**(5): p. 501-511 .
22. Leshin, B. and W. White, *Malignant neoplasms of keratinocytes*. Arndt KA, Leboi PE, Robinson JK, Wintroub BU. Cutaneous medicine and surgery. 1st Ed. Philadelphia. WB: Saunders Company, 1996: p. 1378–.440
23. Mackie, R. and A. Quinn, *Non-Melanoma Skin Cancer and Other Epidermal Skin Tumours*. Rook's Textbook of Dermatology, Seventh Edition, 2004: p. 1801-1850 .
24. Yazdanfar, A. and E. Ghasemi, *Frequency of skin cancers in Hamedan from 1991 to 2007*. Dermatology and Cosmetic, 2011. **2**(2): p. 115-123 .
25. Farmer, K.C. and M.F. Naylor, *Sun exposure, sunscreens, and skin cancer prevention: a year-round concern*. The Annals of pharmacotherapy, 1996. **30**(6): p. 662-673 .
26. Peterson, A.D., H. Downes, and J. Robinson, *Skin cancer risk assessment*. Journal of the American Academy of Dermatology, 2004. **50**(3): p. P8 .
27. Casadevall, A. and M.D. Scharff, *Return to the past: the case for antibody-based therapies in infectious diseases*. Clinical infectious diseases, 1997. **25**(2): p. 150-161 .
28. Newcombe, C. and A.R. Newcombe, *Antibody production: polyclonal-derived biotherapeutics*. Journal of Chromatography B, 2007. **848**(1): p. 2-7 .
29. Dart, R.C., et al., *Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning*. Annals of emergency medicine, 1997. **30**(1): p. 33-39 .
30. Currie, G., *Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancer*. British journal of cancer, 1972. **26**(2): p. 141 .
31. Rosenberg, S.A. and W.D. Terry, *Passive immunotherapy of cancer in animals and man*. Adv Cancer Res, 1977. **25**(323-388): p. 121 .
32. Sharon, J., M.A. Liebman, and B.R. Williams, *Recombinant polyclonal antibodies for cancer therapy*. Journal of cellular biochemistry, 2005. **96**(2): p. 305-313 .
33. Bregenholt, S. and J. Haurum, *Pathogen-specific recombinant human polyclonal antibodies: biodefence applications*. Expert opinion on biological therapy, 2004. **4**(3): p. 387-396 .
34. Dillman, R., *The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy*. Current pharmaceutical biotechnology, 2001. **2**(4): p. 293-300 .
35. Weiner, L.M., R. Surana, and S. Wang, *Monoclonal antibodies: versatile platforms for cancer immunotherapy*. Nature Reviews Immunology, 2010. **10**(5): p. 317-327 .
36. Daneshpour, S., et al., *Immunological cross reaction between cancer cells and hydatid cyst*. Journal of Shahrekord University of Medical Sciences, 2014. **16**(1): p. 99-105 .
37. Fernandez, N.C., et al., *Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo*. Nature medicine, 1999. **5**(4): p. 405-411 .
38. Pillarisetty, V.G., et al., *Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN- $\gamma$  via autocrine IL-12*. The Journal of Immunology, 2005. **174**(5): p. 2612-2618 .
39. Sacconi, A., et al., *p50 nuclear factor- $\kappa$ B overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance*. Cancer research, 2006. **66**(23): p. 11432-11440 .
40. Hung, K., et al., *The central role of CD4+ T cells in the antitumor immune response*. The Journal of experimental medicine, 1998. **188**(12): p. 2357-2368 .
41. Zippelius, A., et al., *Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of*

- local functional tolerance*. Cancer research, 2004. **64**(8): p. 2865-2873 .
42. Knutson, K.L., K. Schiffman, and M.L. Disis, *Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients*. Journal of Clinical Investigation, 2001. **107**(4): p. 477 .
43. Iannello, A. and A. Ahmad, *Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies*. Cancer and Metastasis Reviews, 2005. **24**(4): p. 487-499 .
44. Darani, H.Y. and M. Yousefi, *Parasites and cancers: parasite antigens as possible targets for cancer immunotherapy*. Future Oncology, 2012. **8**(12): p. 1529-1535 .
45. Akgül, H., et al., *Echinococcus against cancer: why not?* Cancer, 2003. **98**(9): p. 1999-2000 .
46. Kallinikova, V., et al., [*Immunization against Trypanosoma cruzi and tumor growth in mice*]. Meditsinskaja parazitologija i parazitarnye bolezni, 2005(4): p. 12-9 .
47. Pidherney, M.S., et al., *In vitro and in vivo tumoricidal properties of a pathogenic/free-living amoeba*. Cancer letters, 1993. **72**(1): p. 91-98 .
48. Mel'nikov, V., F.F. Velasko, and O. Dobrovinskaya, *Suppression of growth and metastasizing of T-cell lymphoma in mice infected with american trypanosomiasis at different stages of experimental infection*. Bulletin of experimental biology and medicine, 2004. **137**(5): p. 475-478 .
49. Kim, J.-O., et al., *Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis*. Journal of Korean medical science, 2007. **22**(Suppl): p. S38-S46 .
50. 宮原和郎, et al., *Antitumor activity of Toxoplasma lysate antigen against methylcholanthrene-induced tumor-bearing rats*. Journal of Veterinary Medical Science, 1992. **54**(2): p. 221-228 .
51. Yousofi Darani, H., et al., *Hydatid cyst protoscolices induce cell death in WEHI-164 fibrosarcoma cells and inhibit the proliferation of baby hamster kidney fibroblasts in vitro*. Journal of parasitology research, 2012. **2012** .
52. Hossein Yousofi, D., *Effect of different hydatid cyst molecules on hela and vero cell lines growth in vitro*. Journal of Immunodeficiency & Disorders, 2013 .
53. Berriel, E., et al., *Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer*. The Scientific World Journal, 2013. **2013** .
54. Chookami, M., et al., *Effect of alive protoscoleces of hydatid cyst on the growth of melanoma cells in mouse model*. J Isfahan Med School, 2014 .
55. Fallon, P., R. Fookes, and M. Doenhoff, *Protection of mice against Schistosoma mansoni infection by passive transfer of sera from infected rabbits*. Parasite immunology, 1996. **18**(1): p. 7-14 .
56. Papazahariadou, M., et al. "Involvement of NK cells against tumors and parasites." *The International journal of biological markers* 22.2 (2006): 144-153.
57. Korb, Daniel S., Olivia C. Finney, and Eleanor M. Riley. "Natural killer cells and innate immunity to protozoan pathogens." *International journal for parasitology* 34.13 (2004): 1517- 1528.
58. Sznol, Mario, et al. "Use of preferentially replicating bacteria for the treatment of cancer." *Journal of Clinical Investigation* 105.8 (2000): 1027.
59. Batmonkh, Zetsegsaikhan, et al. "In vivo anticancer activity of lysates from Trypanosoma cruzi of different genetic groups." *Bulletin of experimental biology and medicine* 142.4 (2006): 470-473.
60. Kallinikova V, Batmonkh T, Kosobokova YN, Pakhorukova L, Ogloblina T, Kravtsov E, et al. Antibodies against Trypanosoma cruzi in intact mice and their oncoprotective effect. MedP;arazitol(Mosk).2008Jan-Mar;(1):11-5.
61. Kallinikova, V. D., et al. "Anticancer Properties of Flagellate Protozoan Trypanosoma cruziChagas, 1909." *Biology Bulletin of the Russian Academy of Sciences* 28.3 (2001): 244-255.



62. Kallinikova VD, Borisova EN, Pakhorukova LV, Ogloblina TA, Batmonkh T, Kravtsov EG, et al. Immunization against *Trypanosoma cruzi* and tumor growth in mice. *Med Parazitol (Mosk)*.2006 Oct-Dec;(4):9-12.
63. Zenina, A. V., et al. "The study of immunological component in antitumor effect of *Trypanosoma cruzi*." *Bulletin of experimental biology and medicine* 145.3 (2008): 352-354.
64. Choo, Juk Dong, et al. "Inhibitory effects of *Toxoplasma* antigen on proliferation and invasion of human glioma cells." *J Korean Neurosurg Soc* 37.2 (2005): 129-136.
65. Darani HY, Shirzad H, Mansoori F, Zabardast N, Mahmoodzadeh M. Effects of *Toxoplasma gondii* and *Toxocara canis* antigens on WEHI-164 fibrosarcoma growth in a mouse model. *Korean JParasitol*.2009Jun;47(2):175-7.
66. Kim JO, Jung SS, Kim SY, Kim TY, Shin DW, Lee JH, et al. Inhibition of Lewis lung carcinoma growth by *Toxoplasma gondii* through induction of Th1 immune responses and inhibition of angiogenesis. *J Korean Med Sci*.2007Sep;22(Suppl):S38-46.
67. Suzuki Y, Muto M, Kobayashi A. Antitumor effect of formalin-fixed *Toxoplasma gondii* organisms on EL4 lymphoma in *Toxoplasma*-infected mice. *J Biol Response Mod*.1986Aug;5(4):288-93.
68. Plumelle Y, Gonin C, Edouard A et al. Effect of *Strongyloides stercoralis* infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia. *Am. J. Clin. Pathol.* 107(1),81-87(1997).
69. Lee, Che-Hsin, Chao-Liang Wu, and Ai-Li Shiau. "Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma." *International Journal of Cancer* 122.4 (2008): 930-935.
70. Gangawar, Ruchika, et al. "Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India." *Medical Oncology* 27.2 (2010): 159-166.
71. Weldon, John E., and Ira Pastan. "A guide to taming a toxin—recombinant immunotoxins constructed from *Pseudomonas* exotoxin A for the treatment of cancer." *FEBS Journal* 278.23 (2011): 4683-4700.
72. Alvarez Errico D, Medeiros A, Miguez M, Casaravilla C, Malgor R, Carmona C, et al. O-glycosylation in *Echinococcus granulosus*: identification and characterization of the carcinoma-associated Tn antigen. *Exp Parasitol*.2001;98(2):100-9.
73. Thors C, Jansson B, Helin H, Linder E. Thomsen-Friedenreich oncofetal antigen in *Schistosoma mansoni*: localization and immunogenicity in experimental mouse infection. *Parasitology*.2006Jan;132(1):73-81.
74. Ubillos L, Medeiros A, Cancela M, Casaravilla C, Dominguez L, et al. Characterization of the carcinoma-associated Tn antigen in helminth parasites. *ExpParasitol*.2007;116(2):129-36.
75. Nyame K, Cummings R, Damian R. *Schistosoma mansoni* synthesizes glycoproteins containing terminal O-linked N-acetylglucosamine residues. *J Biol Chem*. 1987Jun;262(17): 7990 - 7995.
76. Casaravilla C, Freire T, Malgor R, Medeiros A, Osinaga E, Carmona C. Mucin-type O-glycosylation in helminth parasites from major taxonomic groups: evidence for widespread distribution of the Tn antigen (GalNAc-Ser/Thr) and identification of UDP-GalNAc: polypeptide N- acetylgalactosaminyltransferase activity. *JParasitol*.2003Aug;89(4):709-14.
77. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. *Crit Rev Clin LabSci*.2004;41(2):189-231.
78. Chookami, M.B., et al., *Effect of two hydatid cyst antigens on the growth of melanoma cancer in C57/black mice*. *Journal of Parasitic Diseases*, 2015: p. 1-4 .
79. Osinaga, Eduardo. "Expression of cancer-associated simple mucin-type O-glycosylated antigens in parasites." *IUBMB life* 59.4-5 (2007): 269-273.
80. Shambesh, M. K., et al. "IgG1 and IgG4 serum antibody responses in asymptomatic and clinically expressed cystic echinococcosis patients." *Acta Tropica* 64.1 (1997): 53-63.

81. Heimburg, J., et al., *Inhibition of Spontaneous Breast Cancer Metastasis by Anti—Thomsen- Friedenreich Antigen Monoclonal Antibody JAA-F11*. *Neoplasia*, 2006. **8**(11): p. 939-948
82. Araya, L. and A. Winter, *Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum*. *Infection and immunity*, 1990. **58**(1): p. 254-256.
83. Morrison , S.G. and R.P. Morrison, *A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection*. *The Journal of Immunology*, 2005. **175**(11): p. 7536-7542 .
84. Zhigunova, A., et al., *Effects of specific antibodies and immunocompetent cells on tumor growth in passive transfer experiment*. *Bulletin of experimental biology and medicine*, 2013. **154**(6): p. 762-764.
85. Kallinikova, V., et al., *[Antibodies against Trypanosoma cruzi in intact mice and their oncoprotective effect]*. *Meditinskaja parazitologija i parazitarnye bolezni*, 2007(1): p. 11-15.

**Title:** Effect of passive transfer of anti hydatid cyst antigens on growth of melanoma tumor in mouse model.

**Authors:** Fereshteh Jafaei Nodeh<sup>1</sup>, Seyedeh Maryam Sharafi<sup>2</sup>, Sepideh Tulooee<sup>3</sup>, Seyed Hossein Hejazi<sup>4</sup>, Zahra Dorosti<sup>5</sup>, Hossein Yousofi Darani<sup>6</sup>

**Addresses:** Department of parasitology and Mycology, Isfahan university of medical sciences

## **Abstract**

### Introduction

Hydatid cyst is the larval stage of *Echinococcus granulosus*, a parasite responsible for hydatid disease in human and livestock. The Effect of different antigens of this parasite in preventing the growth of tumor cells has been demonstrated in various studies. Therefore, in this study The effect of the injection of antiserum against antigens of hydatid cyst on Melanoma cancer growth In animal models Been checked.

### Methods

In this experimental study, antisera against different antigens of hydatid cyst prepared in rabbits and was injected to C57/black mice and then the mice were subjected to injection with melanoma cells. Finally tumor area in case groups compared with tumor area in groups of control groups. Then, the results analysis by using SPSS software and one way anova test

### Findings

The mean tumor area in mice that received antisera against cyst fluid, protoscolex crude antigen, excretory-secretory antigens of protoscolex and cuticular layer was not significantly different from those of control mice.

## Conclusion

The results of this study showed that injection of antisera against antigens of hydatid cyst in mice received melanoma cells had no significant effect on tumor growth. So it is recommended that effect of transfer of immune cells is investigated in future studies.

**Keywords:** Antiserum, tumor, antigens, hydatid cyst, Passive Immunization